An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Clinical trial NCT03601078 · COMPLETED
Trial details
- NCT number
- NCT03601078
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-13
- Primary completion
- 2026-01-15
- Enrollment
- 312
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.